Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 33

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 33
---
 elected. You may vote FOR all the nominees, FOR any one of the nominees, WITHHOLD your vote from all the nominees or WITHHOLD your vote from any one of the nominees. Withheld votes and broker non-votes will have no effect on the election of directors.

The proxies will be voted in favor of the above nominees unless a contrary specification is made in the proxy. The nominees have consented to serve as our directors if elected. However, if the nominees are unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as our Board of Directors may designate.

The proposal for the election of directors relates solely to the election of Class III directors nominated by our Board of Directors.

THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” THE ELECTION OF EACH OF THESE NOMINEES FOR CLASS III DIRECTOR, AND PROXIES SOLICITED BY OUR BOARD WILL BE VOTED IN FAVOR THEREOF, UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY.

<div align='center'>(PROPOSAL 1 ON YOUR NOTICE OR PROXY CARD)

21</div>

### EXECUTIVE OFFICERS
Below is a list of the names, ages as of April 22, 2025 and positions, and a brief account of the business experience of the individuals who serve as our executive officers. Andrew Anzalone is included in his capacity as a significant employee.

| Name                              |     | Age |     | Position                                                 |
| Keith Gottesdiener, M.D.          |     |  71 |     | President, Chief Executive Officer and Director          |
| Richard Brudnick                  |     |  68 |     | Chief Business Officer                                   |
| Jeremy Duffield, M.D. Ph.D., FRCP |     |  57 |     | Chief Scientific Officer                                 |
| Ann Lee, Ph.D.                    |     |  63 |     | Chief Technical Officer                                  |
| Allan Reine, M.D.                 |     |  50 |     | Chief Financial Officer                                  |
| Meredith Goldwasser, Sc.D.        |     |  54 |     | Senior Vice President, Strategy and Corporate Operations |
| Andrew Anzalone, M.D., Ph.D.      |     |  38 |     | Co-Founder and Head of Prime Editing Platform            |

#### Executive Officer Biographies
The